Stryker stock
SYKNYSEStryker Corporation, HealthcareISIN US8636671013
70Score 70 out of 100, Strong
Price and trend
66 / 100
Price history
−12% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.1% below it.
Since October 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 18% below its 52-week high. Largest decline in 20 years: 59% (December 2007 to March 2009).
Chart figures for advanced users
- SMA 50$292.21
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$322.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$269.75
- The lowest closing price of the last twelve months.
- Resistance$387.46
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Stryker Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $121.36B, is number 3 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $25.12B (up 11.2% year on year) and earnings of $3.25B (up 8.5%).
- For fiscal 2026, analysts expect on average revenue of $26.82B (up 6.8%) and adjusted earnings per share of $14.84 (up 8.8%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 148 of 714 in Healthcare, median 53.
- The P/E is 33.9 (Medical (Devices) median 29, own median of recent years 40.3).
- Our model puts fair value at $294.09, with the price 8% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 33 years.Capital allocation 62
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 89
- Earnings turn into cashFree cash flow 126% of earnings over the last 12 months.Fundamentals 89
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and stability, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 71 to 70.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $226.22 and expensive above $420.12 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $314.87 (cash-flow model) and $273.30 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $266.69, at 7.8% it would be $335.27.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 7.9% on the twelve months before. Revenue has grown solidly since 2006, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 64%, operating 19%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 29 Oct 2026EPS reported $3.52 (expected $3.55)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $14.84−0.9%
- Revenue
- $26.82B−1.4%
- Earnings per share
- $16.31−2.3%
- Revenue
- $28.71B−2.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −7.5%Guidance narrowed: organic net sales growth 8.3% to 9.3% (bottom end raised from 8%) and adjusted EPS $14.95 to $15.10, with the top end of the range lowered.
“Considering our year to date results, our presence in attractive end markets largely supporting acute and emergent procedures and durable demand for our capital products, we are narrowing our full year guidance and now expect organic net sales growth to be in the range of 8.3% to 9.3% and adjusted net earnings per …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $395.31M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Stryker Ronda ESale
6 Nov 2026, Board
- Shares
- 550,000
- Price
- $325.32
- Value
- $178.92M
- Crotty Dylan BramSale
21 Aug 2026, Group President
- Shares
- 441
- Price
- $328.61
- Value
- $144,915
- Stryker Ronda ESale
19 Aug 2026, Board
- Shares
- 50,000
- Price
- $340.10
- Value
- $17.01M
Show 4 more
- Stryker Ronda ESale
18 Aug 2026, Board
- Shares
- 300,000
- Price
- $335.90
- Value
- $100.77M
- King DebraSale
18 Aug 2026, See Remarks
- Shares
- 826
- Price
- $336.30
- Value
- $277,787
- Fletcher Robert SSale
28 May 2026, VP, Chief Legal Officer
- Shares
- 4,544
- Price
- $306.87
- Value
- $1.39M
- Stryker Ronda ESale
26 May 2026, Board
- Shares
- 310,000
- Price
- $312.23
- Value
- $96.79M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Stryker
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Abbott LaboratoriesABT $189.28B63
- Medtronic PlcMDT $129.98B70
- Boston ScientificBSX $65.41B63
- Edwards LifesciencesEW $60.84B76
- Siemens HealthineersSHL.DE $54.2B65
- GE HealthCare TechnologiesGEHC $37.35B69
- Shenzhen Mindray Bio-Medical Electronics300760.SZ $32.12B75
- DexComDXCM $29.97B78
ETFs that hold Stryker
Held by 123 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.01% | 0.49% | €318.39M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 1.75% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.72% | 0.15% | €3.27B |
Show 5 more
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 1.70% | 0.12% | €1.34B |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.66% | 0.18% | €837.43M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 1.26% | 0.25% | €4.18B |
| iShares MSCI USA SRI UCITS ETFQDVR | 0.84% | 0.20% | €2.98B |
| UBS MSCI USA Socially Responsible UCITS ETF USD disUIMP | 0.77% | 0.22% | €1.04B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.